News & Comment

Filter By:

Article Type
Year

  • John Lechleiter, the retiring Chief Executive Officer at Eli Lilly, discusses his path from the chemistry lab to the executive suite.

    An Audience With

  • Carole Ho, Chief Medical Officer at Denali Therapeutics, discusses how genetic findings have paved the way for one of the largest start-ups to take on neurodegeneration.

    An Audience With

  • Deborah Zarin, director ofClinicalTrials.gov, discusses the new trial registration rules and the need for transparency in the clinical research enterprise.

    An Audience With

  • Michael Rosenblatt, newly appointed Chief Medical Officer of Flagship Ventures and former Chief Medical Officer at Merck & Co., discusses his move from industry to venture capital.

    An Audience With

  • Melissa Paoloni, an architect of the I-SPY 2 trial at QuantumLeap Healthcare Collaborative, discusses the evolution of one of the first adaptive, umbrella trials.

    An Audience With

  • Jim O'Neill, chair of the United Kingdom's review into antimicrobial resistance, says industry needs to up its game in the battle against antimicrobial resistance.

    An Audience With

  • Philip Tetlock, author of Superforecasting, discusses how the pharmaceutical industry can make better predictions.

    An Audience With

  • Alan Shuldiner, co-head of the Regeneron Genetics Center, says that the time for genomic drug discovery has arrived.

    An Audience With

  • Stevin Zorn, executive scientist in residence at Lundbeck Research USA, discusses the growing interest in how inflammation might drive Alzheimer disease and mood disorders.

    An Audience With

  • Arthur Caplan, a medical ethicist at the New York University School of Medicine, discusses how to fairly distribute experimental drugs outside of clinical trials.

    An Audience With

  • Ian Tomlinson, former head of business development for GlaxoSmithKline and now chairman of the Apollo Therapeutics Fund, discusses a new model of pharmaceutical–academic partnership.

    An Audience With

  • Michael Hanson, president of the GPCR Consortium, discusses how industry and academic partners are shedding light on one of the most important classes of drug targets.

    An Audience With